S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC

from OncLive® On Air · host OncLive® On Air

Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.

Episode metadata supplied by the publisher feed · Published Nov 24, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC

0:00 18:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 18 minutes long.

When was this OncLive® On Air episode published?

This episode was published on November 24, 2022.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!